Evidence map›Paper›PMID 41431875›Full record

ArticleEpidemiology and infection2025

Evaluating a quality improvement intervention for schistosomiasis mass drug administration in Ghana using the RE-AIM framework.

Nicole Vernot-Jonas, Alfred Kwesi Manyeh

Abstract read
In one paragraph

Article in Epidemiology and infection, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Nicole Vernot-JonasDepartment of Global Health, https://ror.org/05vzafd60Georgetown University, USA.ORCID 0009-0006-7748-3794
Alfred Kwesi ManyehInstitute of Health Research, https://ror.org/054tfvs49University of Health and Allied Sciences, Ghana.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite efforts by the Volta River Authority (VRA) to provide services for schistosomiasis control in communities along Ghana's Volta Basin, high rates of transmission and re-infection persist in the region. To strengthen intervention effectiveness, the VRA partnered with the University of Health and Allied Sciences to conduct implementation research aimed at developing context-specific, evidence-based quality improvement strategies. This mixed-method study evaluates the reach, effectiveness, adoption, implementation, and maintenance of the VRA's quality improvement intervention for their mass drug administration (MDA) for schistosomiasis. Baseline and endline surveys were analysed using STATA and qualitative data from in-depth interviews (IDIs) and focus group discussions (FGDs) were coded and analysed thematically using Taguette. Urogenital schistosomiasis prevalence decreased by 87.83% in Shai Osudoku, 88.98% in South Tongu, and 90.96% in Asuogyaman after the intervention. The findings revealed high training levels among district health management staff and community drug distributors, high health worker satisfaction with the training, and positive community reception of the intervention. However, praziquantel side effects and related opportunity costs may have posed a barrier to drug uptake. Moreover, re-infection remains a challenge, which could be attributed to high domestic and economic reliance on the Volta River.

Indexed as

AnthelminticsMass Drug AdministrationPraziquantelQuality ImprovementSchistosomiasisAdolescentAdultFemaleGhanaHumansMaleMiddle AgedPrevalenceYoung AdultAnthelminticsPraziquantelGhanaMass drug administrationRE-AIM FrameworkSchistosomiasis (bilharziasis)Volta Region

Identifiers

PMID41431875
PMCPMC12813720

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.